Skandinaviska Enskilda Banken (SEB)
CRNX icon

Skandinaviska Enskilda Banken (SEB)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-213,891
Closed -$9.96M – 294
2025
Q4 		$9.96M Buy
213,891
+35,307
+20% +$1.57M 0.04% 285
2025
Q3 		$7.44M Buy
178,584
+160,467
+886% +$5.13M 0.03% 336
2025
Q2 		$521K Hold
18,117
– – ﹤0.01% 699
2025
Q1 		$608K Hold
18,117
– – ﹤0.01% 674
2024
Q4 		$918K Buy
+18,117
New +$1.01M ﹤0.01% 664

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s CRNX Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 213,891 shares — an estimated $9.96M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in CRNX in Q4 2024 and held it in 5 quarters. The position peaked at $9.96M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 213,891 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $9.96M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Crinetics Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Crinetics Pharmaceuticals position peaked at $9.96M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.